Quantcast
Channel: All News Releases
Viewing all 161058 articles
Browse latest View live

Genuine Aesthetics Now Offering Anti-Wrinkle Treatment at its NYC Medical Spa


iPatientCare, Inc. Successfully Concludes its National User Conference (NUCON) 2018 with Great Success

Cindy Ashton’s “Innovation Uncorked” Launches North American Tour; Premieres January 2019 on e360TV

ASAP Systems Announces How Its Inventory System Has Assisted Penske Vehicle Service with Their Asset Tracking Solution

Amber Ridinger-McLaughlin Launches Her Lumiere de Vie® Hommes Skin Care Line For Men Alongside Jamie Foxx Aboard Superyacht Utopia IV In New York Harbor

0
0

On Saturday evening, millennial serial entrepreneur Amber Ridinger-McLaughlin, the creator of the Lumiere de Vie® skin care line, co-hosted a launch party for her new line of men’s skin care products, Lumiere de Vie Hommes®. The event was held aboard the Ridinger family superyacht, the brand new Utopia IV, and was co-hosted by Academy Award winner and super talent Jamie Foxx.

(PRWeb October 16, 2018)

Read the full story at https://www.prweb.com/releases/amber_ridinger_mclaughlin_launches_her_lumiere_de_vie_hommes_skin_care_line_for_men_alongside_jamie_foxx_aboard_superyacht_utopia_iv_in_new_york_harbor/prweb15843534.htm

IgniteNet’s 60GHz MetroLinq Receives Product of the Year Award

Berkshire Hathaway HomeServices PenFed Realty Launches New Listing Automation Platform

Infinite Electronics, Inc. to be Represented at the Society of Women Engineers’ WE18 Conference


RadioWaves Launches New Enhanced Standard Performance (ESP) Antenna Line

Intrinsic Clinical Systems Announces Release of Time Tracking Tool, Intrinsic InTime

Ashley Mabery Joins CloudOne as Sr. Director of Product

Chris Sands Joins MineralTree as Chief Financial Officer

Multi-Housing Marketing Webinar – How to Build Your Property’s Digital Curb Appeal

New ‘Can’t Catch Harry’ Card Game from Odd 1s Out Surpasses $200,000 in Presales on Kickstarter

People’s Trust Home Insurance – First to Respond in Michael’s Wake


Catalent and Verastem Oncology Partner on Newly Launched, FDA Approved COPIKTRA™ (duvelisib) Capsules

0
0

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed the approval of Verastem Oncology’s COPIKTRA™ (duvelisib) capsules by the U.S. Food and Drug Administration (FDA). COPIKTRA is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.

(PRWeb October 16, 2018)

Read the full story at https://www.prweb.com/releases/catalent_and_verastem_oncology_partner_on_newly_launched_fda_approved_copiktra_duvelisib_capsules/prweb15844172.htm

Security Industry Association Forecasts 2019 Security Megatrends

Is Your Home Safe? Home Improvement Hosts, Danny Lipford & Chelsea Lipford Wolf, Share Expert Tips in National Media Event

The Rise of the Recurring and Subscription Payments Market

Worcester Polytechnic Institute Students Gain Foothold with New Athletic Shoe Sole

Viewing all 161058 articles
Browse latest View live




Latest Images